153 related articles for article (PubMed ID: 26111384)
1. Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Kandela I; Jin HY; Owen K;
Elife; 2015 Jun; 4():e07072. PubMed ID: 26111384
[TBL] [Abstract][Full Text] [Related]
2. Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Aird F; Kandela I; Mantis C;
Elife; 2017 Jan; 6():. PubMed ID: 28100400
[TBL] [Abstract][Full Text] [Related]
3. Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia.
Fung JJ; Kosaka A; Shan X; Danet-Desnoyers G; Gormally M; Owen K; ;
Elife; 2015 Sep; 4():. PubMed ID: 26327698
[TBL] [Abstract][Full Text] [Related]
4. BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Delmore JE; Issa GC; Lemieux ME; Rahl PB; Shi J; Jacobs HM; Kastritis E; Gilpatrick T; Paranal RM; Qi J; Chesi M; Schinzel AC; McKeown MR; Heffernan TP; Vakoc CR; Bergsagel PL; Ghobrial IM; Richardson PG; Young RA; Hahn WC; Anderson KC; Kung AL; Bradner JE; Mitsiades CS
Cell; 2011 Sep; 146(6):904-17. PubMed ID: 21889194
[TBL] [Abstract][Full Text] [Related]
5. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract][Full Text] [Related]
6. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
[TBL] [Abstract][Full Text] [Related]
7. Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Sharma V; Young L; Cavadas M; Owen K;
Elife; 2016 Mar; 5():. PubMed ID: 26999821
[TBL] [Abstract][Full Text] [Related]
8. Registered report: Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis.
Fiering S; Ang LH; Lacoste J; Smith TD; Griner E;
Elife; 2015 Jul; 4():e04796. PubMed ID: 26179155
[TBL] [Abstract][Full Text] [Related]
9. Registered report: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology.
Khan I; Kerwin J; Owen K; Griner E; ;
Elife; 2015 Sep; 4():. PubMed ID: 26335297
[TBL] [Abstract][Full Text] [Related]
10. Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma.
Lee S; Rellinger EJ; Kim KW; Craig BT; Romain CV; Qiao J; Chung DH
Surgery; 2015 Sep; 158(3):819-26. PubMed ID: 26067464
[TBL] [Abstract][Full Text] [Related]
11. Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.
Haven B; Heilig E; Donham C; Settles M; Vasilevsky N; Owen K; ;
Elife; 2016 Feb; 5():. PubMed ID: 26905833
[TBL] [Abstract][Full Text] [Related]
12. Registered report: Interactions between cancer stem cells and their niche govern metastatic colonization.
Incardona F; Doroudchi MM; Ismail N; Carreno A; Griner E; Anna Lim M;
Elife; 2015 Jun; 4():e06938. PubMed ID: 26086719
[TBL] [Abstract][Full Text] [Related]
13. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
[TBL] [Abstract][Full Text] [Related]
14. Registered report: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment.
Evans J; Essex A; Xin H; Amitai N; Brinton L; Griner E; ;
Elife; 2015 Aug; 4():. PubMed ID: 26287525
[TBL] [Abstract][Full Text] [Related]
15. Registered report: Melanoma genome sequencing reveals frequent PREX2 mutations.
Chroscinski D; Sampey D; Hewitt A;
Elife; 2014 Dec; 3():. PubMed ID: 25490935
[TBL] [Abstract][Full Text] [Related]
16. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
17. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
Yao W; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225
[TBL] [Abstract][Full Text] [Related]
18. Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
Bhargava A; Anant M; Mack H; ;
Elife; 2016 Feb; 5():. PubMed ID: 26885666
[TBL] [Abstract][Full Text] [Related]
19. Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Evans B; Griner E;
Elife; 2015 Jul; 4():e07420. PubMed ID: 26231040
[TBL] [Abstract][Full Text] [Related]
20. Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells.
Vanden Heuvel JP; Bullenkamp J;
Elife; 2016 Jun; 5():. PubMed ID: 27336789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
